• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Hikma Pharmaceuticals Plc ADR (OP:HKMPY)

    41.73 -0.20 (-0.47%)
    Streaming Delayed Price Updated: 2:54 PM EST, Jan 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Hikma Pharmaceuticals Plc ADR

    News headline image
    Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
    Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada 
    From Emergent BioSolutions
    Via GlobeNewswire
    News headline image
    Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
    From Guardant Health, Inc.
    Via Business Wire
    News headline image
    Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
    From Junshi Biosciences
    Via GlobeNewswire
    News headline image
    Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)
    From Bio-Thera Solutions, Ltd.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.